ניאצין

עדיין אין קונצנזוס בסיפרות העולמית-מצרף לך 2 רפרנסים:
Niacin not beneficial in patients at goal with statins: NIA Plaque
The addition of niacin to statin therapy in secondary-prevention patients resulted in a significant improvement in LDL- and HDL-cholesterol levels but failed to significantly alter atherosclerotic disease progression as measured by MRI, compared with statin therapy alone.
The results, from the NIA Plaque study, are in contrast with the findings from the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER 6-HALTS) study and with a recent imaging study showing that niacin helped with plaque regression when used on top of optimized statin therapy, but investigators say the patient populations differ significantly.

ARBITER 6-HALTS: HDL raising with niacin superior to ezetimibe
Adding extended-release niacin (Niaspan, Abbott) to statin therapy results in a significant regression of atherosclerosis as measured by carotid intima-media thickness (IMT), whereas the addition of ezetimibe (Zetia, Merck/Schering-Plough) to statin therapy did not, according to an eagerly anticipated study